OBJECTIVES The aim of this study was to examine which component of drug-eluting stents (DES) plays a major role in enhanced coronary vasoconstricting responses after DES implantation in pigs.
D rug-eluting stents (DES) have been used most frequently in the field of interventional cardiology worldwide (1) . Antiproliferative drug-elution of DES, which is controlled for a fixed period by a polymer coating, has dramatically inhibited neointimal formation and consequent risk of in-stent restenosis (2) . Despite these beneficial aspects, DES show no beneficial prognostic effect compared with conventional bare metal stents (3) . Notably, several largescale trials demonstrated that 30% of patients with stable angina were still symptomatic 1 year after successful percutaneous coronary intervention (PCI) (4) and that an initial improvement of angina immediately after revascularization was minimized at 3-year follow-up compared with medical treatment (5) . Surprisingly, new or worsening angina was also documented in patients who underwent successful PCI with the most promising product, everolimus-eluting stents (EES) (6) .
Recently, impaired coronary vasomotion after DES implantation has been reported (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) as a cause of new or unremitting angina and a predictor of poor vascular healing and subsequent stent thrombosis. Indeed, we have demonstrated that DES-induced coronary hyper-reactivity causes sudden cardiac arrest even after coronary revascularization (15) . Thus, DES-induced coronary hyperconstricting responses are an emerging concern in the long-term safety of DES implantation.
We previously demonstrated that activation of a Rho-kinase pathway, which we have identified as the central molecular mechanism of coronary spasm (16) (17) (18) (19) , is involved in the pathogenesis of DESinduced coronary hyperconstricting responses in animals (11) (12) (13) and humans (14) and that inflammatory changes from DES subsequently cause Rhokinase activation (12) (13) (14) . A DES consists of 3 major components: a metal stent, a polymer coating, and an antiproliferative drug (1) . Although a polymer coating could promote inflammatory changes (20, 21) , it remains to be fully elucidated which component of a DES plays a major role in DES-induced coronary hyperconstricting responses.
To eliminate the unfavorable effects of DES, a sophisticated biocompatible device is warranted. A poly-DL-lactic acid and polycaprolactone (PDLLA-PCL) copolymer matrix has been recently developed as an innovative polymer technology with higher biocompatibility and is resorbed within 3 months (22,23), whereas the current polylactic acid (PLA) biocompatible polymers are resorbed for up to 6 months (24).
In the present study, we thus examined whether a polymer coating is responsible for DES-induced coronary hyperconstricting responses through Rhokinase activation in pigs in vivo and, if so, whether novel PDLLA-PCL copolymer technology ameliorates coronary hyperconstricting responses. Table 1 ).
METHODS

CORONARY VASOMOTION AT 1 MONTH AFTER
STENT IMPLANTATION. At 1 month after stent implantation, no significant in-stent restenosis was observed in the 4 groups (Figures 2A, 2D , 2G, and 2J). Nishimiya et al.
Polymer and DES-Induced Coronary Hyperconstriction Table 2 ). Endothelialization was almost complete at the 4 sites, although slightly less at the P1þDþ sites compared with the other 3 sites (Online Table 2 ). At the stent edges, no significant difference in the histomorphometry was noted at the 4 stent sites (Online Table 3 ).
FIGURE 1 Study Protocol
The 4 different stents, P1þDþ, P1þDÀ, P2þDÀ, and PÀDÀ (6 each), were randomly implanted in the LAD and LCX in 12 miniature pigs. At 1 month after stent implantation, animals underwent follow-up coronary angiography to assess coronary vasomotion in vivo and were then euthanized for histological and immunohistological analyses of the inflammation and expression/activity of Rho-kinase. IC ¼ intracoronary;
LAD ¼ left anterior descending coronary artery; LCX ¼ left circumflex coronary artery; PÀDÀ ¼ stent without a polymer or a drug; P1þDþ ¼ stent with a polylactic acid polymer and a drug; P1þDÀ ¼ stent with a polylactic acid polymer but without a drug; P2þDÀ stent with a poly-DLlactic acid and polycaprolactone copolymer but without a drug; PDLLA-PCL ¼ poly-DL-lactic acid and polycaprolactone; PLA ¼ polylactic acid. Nishimiya et al.
INFLAMMATORY CHANGES IN THE STENT SITES
Polymer and DES-Induced Coronary Hyperconstriction The high prevalence of coronary vasomotor abnormalities after PCI (w50%) was recently reported (25) . Impaired coronary vasomotion is associated with increased cardiovascular risks (26) . Indeed,
we recently reported on a patient who had cardiac arrest associated with DES-induced coronary hyperconstriction (15) . Thus, more attention should be paid to coronary hyperconstricting responses and resulting new or worsening angina after successful PCI with DES.
A DES consists of 3 components: a metal stent, a polymer coating, and an antiproliferative drug (1).
Although a polymer coating is necessary to permit the drug release kinetics for a fixed period, persistent polymer residues in the coronary arterial wall may be most responsible for the late-phase Figure 1 .
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inflammatory changes after DES implantation (20).
We have also demonstrated that sirolimus-eluting stents enhance coronary vasoconstricting responses compared with its platform bare metal stents through inflammatory changes and subsequent Rhokinase activation in pigs and humans (11, 14) , suggesting that the polymer coating or the eluting drug, but not the metal stent, may be responsible for the DES-induced coronary hyperconstricting responses. In the present study, all of the coronary stents were made of stainless steel with 120-mm-thick strut to precisely evaluate the effects of a polymer coating and an eluting drug (Online Figure 1) . Although it has been hypothesized that hyperreactivity to a polymer coating is involved in the impairment of coronary vasoconstriction (7-13), the influence of each stent component remains to be fully elucidated. In the present study, we were able to demonstrate that removal of both a PLA polymer coating and an eluting drug from DES system (PÀDÀ) significantly reduced coronary hyperconstricting responses, whereas drug removal alone (P1þDÀ) was insufficient. These results thus provide the first direct evidence that polymer coating residues play a major role in the coronary hyperconstricting responses after DES implantation.
POTENTIAL BENEFITS OF PDLLA-PCL COPOLYMERS ON DES-INDUCED CORONARY HYPERREACTIVITY.
Polymer blends of the PDLLA and the PCL matrix, We previously demonstrated that Rho-kinase inhibitors are effective for coronary spasm in patients with vasospastic angina (16) (17) (18) (19) remain to be elucidated (Online Figure 1 ). However,
we were able to demonstrate the beneficial effects of novel biocompatible PDLLA-PCL copolymers compared with the PLA polymers. Third, we used serotonin to examine coronary vasoconstricting responses, as previously described (11) (12) (13) (16) (17) (18) .
Although acetylcholine is most frequently used to provoke coronary artery spasm in the clinical setting, serotonin may better mimic spontaneous coronary spasm in humans than acetylcholine (33) .
Finally, the effects of endothelial shear stress on the altered vascular responses after stent implantation remain to be examined in future studies.
However, for precise quantitative coronary angiography analysis, the stents were gently deployed across the major side branches in the present study, predisposed to the development of low endothelial shear stress and subsequent inflammatory changes (34) . Furthermore, all parameters evaluated in the present study were not affected by the measurement position (e.g., proximal site vs. distal site). Because endothelial shear stress is also driven by the thick-strut stents (35), thinner strut stents (1,24) may be useful to address this issue in future studies. WHAT IS NEXT? Thus, a novel DES system using a PDLLA-PCL copolymer could be a promising device to reduce vasomotion abnormalities after DES implantation.
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